Copyright Reports & Markets. All rights reserved.

(Post-pandemic Era)-Global Oral Solid Dosage Contract Manufacturing Market Segment Research Report 2022

Buy now

Table of Contents

    Global Oral Solid Dosage Contract Manufacturing Market Segment Research Report 2022

      1. Research Scope

        2. Market Overview

        • 2.1 Product Introduction, Application, Picture
        • 2.2 Global Oral Solid Dosage Contract Manufacturing Market by Value
          • 2.2.1 Global Oral Solid Dosage Contract Manufacturing Revenue by Type
          • 2.2.2 Global Oral Solid Dosage Contract Manufacturing Market by Value (%)
        • 2.3 Global Oral Solid Dosage Contract Manufacturing Market by Production
          • 2.3.1 Global Oral Solid Dosage Contract Manufacturing Production by Type
          • 2.3.2 Global Oral Solid Dosage Contract Manufacturing Market by Production (%)

        3. The Major Driver of Oral Solid Dosage Contract Manufacturing Industry

        • 3.1 Historical & Forecast Global Oral Solid Dosage Contract Manufacturing Demand
        • 3.2 Largest Application for Oral Solid Dosage Contract Manufacturing (2018-2028)
        • 3.3 The Major Downstream Company in China Market 2022

        4. Global and Regional Oral Solid Dosage Contract Manufacturing Market

        • 4.1 Regional Market Size in Terms of Production & Demand (2022)
        • 4.2 Regional Market Share in Terms of Revenue (2018-2022)
        • 4.3 Concentration Ratio (CR5& CR10) of Oral Solid Dosage Contract Manufacturing Market
        • 4.4 Mergers & Acquisitions, Expansion Plans

        5. US Oral Solid Dosage Contract Manufacturing Production, Demand (2018-2028)

        • 5.1 Current and Estimated Production Breakdown by Type
        • 5.2 Current and Estimated Demand Breakdown by Type
        • 5.3 Current and Estimated Demand Breakdown by Application
        • 5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        6. Europe Oral Solid Dosage Contract Manufacturing Production, Demand (2018-2028)

        • 6.1 Current and Estimated Production Breakdown by Type
        • 6.2 Current and Estimated Demand Breakdown by Type
        • 6.3 Current and Estimated Demand Breakdown by Application
        • 6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        7. China Oral Solid Dosage Contract Manufacturing Production, Demand (2018-2028)

        • 7.1 Current and Estimated Production Breakdown by Type
        • 7.2 Current and Estimated Demand Breakdown by Type
        • 7.3 Current and Estimated Demand Breakdown by Application
        • 7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        8. Japan Oral Solid Dosage Contract Manufacturing Production, Demand (2018-2028)

        • 8.1 Current and Estimated Production Breakdown by Type
        • 8.2 Current and Estimated Demand Breakdown by Type
        • 8.3 Current and Estimated Demand Breakdown by Application
        • 8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        9. India Oral Solid Dosage Contract Manufacturing Production, Demand (2018-2028)

        • 9.1 Current and Estimated Production Breakdown by Type
        • 9.2 Current and Estimated Demand Breakdown by Type
        • 9.3 Current and Estimated Demand Breakdown by Application
        • 9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        10. Korea Oral Solid Dosage Contract Manufacturing Production, Demand (2018-2028)

        • 10.1 Current and Estimated Production Breakdown by Type
        • 10.2 Current and Estimated Demand Breakdown by Type
        • 10.3 Current and Estimated Demand Breakdown by Application
        • 10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        11. Southeast Asia Oral Solid Dosage Contract Manufacturing Production, Demand (2018-2028)

        • 11.1 Current and Estimated Production Breakdown by Type
        • 11.2 Current and Estimated Demand Breakdown by Type
        • 11.3 Current and Estimated Demand Breakdown by Application
        • 11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        12. Global Oral Solid Dosage Contract Manufacturing Average Price Trend

        • 12.1 Market Price for Each Type of Oral Solid Dosage Contract Manufacturing in US (2018-2022)
        • 12.2 Market Price for Each Type of Oral Solid Dosage Contract Manufacturing in Europe (2018-2022)
        • 12.3 Market Price for Each Type of Oral Solid Dosage Contract Manufacturing in China (2018-2022)
        • 12.4 Market Price for Each Type of Oral Solid Dosage Contract Manufacturing in Japan (2018-2022)
        • 12.5 Market Price for Each Type of Oral Solid Dosage Contract Manufacturing in India (2018-2022)
        • 12.6 Market Price for Each Type of Oral Solid Dosage Contract Manufacturing in Korea (2018-2022)
        • 12.7 Market Price for Each Type of Oral Solid Dosage Contract Manufacturing in Southeast Asia (2018-2022)

        13. Industrial Chain (Impact of COVID-19)

        • 13.1 Oral Solid Dosage Contract Manufacturing Industrial Chain Analysis
        • 13.2 Downstream
        • 13.3 Impact of COVID-19
        • 13.4 Post-pandemic Era
        • 13.5 Technology Trends of Oral Solid Dosage Contract Manufacturing

        14. Oral Solid Dosage Contract Manufacturing Competitive Landscape

        • 14.1 Catalent
          • 14.1.1 Catalent Company Profiles
          • 14.1.2 Catalent Product Introduction
          • 14.1.3 Catalent Oral Solid Dosage Contract Manufacturing Sales, Revenue (2018-2022)
          • 14.1.4 Strategic initiatives
        • 14.2 DPx
          • 14.2.1 DPx Company Profiles
          • 14.2.2 DPx Product Introduction
          • 14.2.3 DPx Oral Solid Dosage Contract Manufacturing Sales, Revenue (2018-2022)
          • 14.2.4 Strategic initiatives
        • 14.3 Lonza Group (Capsugel)
          • 14.3.1 Lonza Group (Capsugel) Company Profiles
          • 14.3.2 Lonza Group (Capsugel) Product Introduction
          • 14.3.3 Lonza Group (Capsugel) Oral Solid Dosage Contract Manufacturing Sales, Revenue (2018-2022)
          • 14.3.4 Strategic initiatives
        • 14.4 Piramal Pharma Solutions
          • 14.4.1 Piramal Pharma Solutions Company Profiles
          • 14.4.2 Piramal Pharma Solutions Product Introduction
          • 14.4.3 Piramal Pharma Solutions Oral Solid Dosage Contract Manufacturing Sales, Revenue (2018-2022)
          • 14.4.4 Strategic initiatives
        • 14.5 Aenova
          • 14.5.1 Aenova Company Profiles
          • 14.5.2 Aenova Product Introduction
          • 14.5.3 Aenova Oral Solid Dosage Contract Manufacturing Sales, Revenue (2018-2022)
          • 14.5.4 Strategic initiatives
        • 14.6 Jubilant
          • 14.6.1 Jubilant Company Profiles
          • 14.6.2 Jubilant Product Introduction
          • 14.6.3 Jubilant Oral Solid Dosage Contract Manufacturing Sales, Revenue (2018-2022)
          • 14.6.4 Strategic initiatives
        • 14.7 Famar
          • 14.7.1 Famar Company Profiles
          • 14.7.2 Famar Product Introduction
          • 14.7.3 Famar Oral Solid Dosage Contract Manufacturing Sales, Revenue (2018-2022)
          • 14.7.4 Strategic initiatives
        • 14.8 Boehringer Ingelheim
          • 14.8.1 Boehringer Ingelheim Company Profiles
          • 14.8.2 Boehringer Ingelheim Product Introduction
          • 14.8.3 Boehringer Ingelheim Oral Solid Dosage Contract Manufacturing Sales, Revenue (2018-2022)
          • 14.8.4 Strategic initiatives
        • 14.9 Fareva Holding
          • 14.9.1 Fareva Holding Company Profiles
          • 14.9.2 Fareva Holding Product Introduction
          • 14.9.3 Fareva Holding Oral Solid Dosage Contract Manufacturing Sales, Revenue (2018-2022)
          • 14.9.4 Strategic initiatives
        • 14.10 AbbVie Contract Manufacturing
          • 14.10.1 AbbVie Contract Manufacturing Company Profiles
          • 14.10.2 AbbVie Contract Manufacturing Product Introduction
          • 14.10.3 AbbVie Contract Manufacturing Oral Solid Dosage Contract Manufacturing Sales, Revenue (2018-2022)
          • 14.10.4 Strategic initiatives
        • 14.11 Nipro Pharma
        • 14.12 Sopharma
        • 14.13 Mylan (DPT Laboratories)
        • 14.14 Recipharm
        • 14.15 NextPharma
        • 14.16 Dishman
        • 14.17 Aesica Pharmaceuticals
        • 14.18 CordenPharma

        15. Conclusion

          16. Methodology and Data Source

          Summary

          The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.

          2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.

          According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.

          Beijing Yanjing Bizhi Information Consulting Co., Ltd. (XYZResearch)released the 《(Post-pandemic Era)-Global Oral Solid Dosage Contract Manufacturing Market Segment Research Report 2022》, which aims to sort out the development status and trends of the Oral Solid Dosage Contract Manufacturing industry at home and abroad, estimate the overall market scale of the Oral Solid Dosage Contract Manufacturing industry and the market share of major countries, Oral Solid Dosage Contract Manufacturing industry, and study and judge the downstream market demand of Oral Solid Dosage Contract Manufacturing through systematic research, Analyze the competition pattern of Oral Solid Dosage Contract Manufacturing, so as to help solve the pain points of various stakeholders in Oral Solid Dosage Contract Manufacturing industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.

          Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Oral Solid Dosage Contract Manufacturing Market by XYZResearch Include
          USA
          Europe
          China
          Japan
          India
          Korea
          Southeast Asia
          Competitive Analysis; Who are the Major Players in Oral Solid Dosage Contract Manufacturing Market?
          Catalent
          DPx
          Lonza Group (Capsugel)
          Piramal Pharma Solutions
          Aenova
          Jubilant
          Famar
          Boehringer Ingelheim
          Fareva Holding
          AbbVie Contract Manufacturing
          Nipro Pharma
          Sopharma
          Mylan (DPT Laboratories)
          Recipharm
          NextPharma
          Dishman
          Aesica Pharmaceuticals
          CordenPharma
          Major Type of Oral Solid Dosage Contract Manufacturing Covered in XYZResearch report:
          Tablets
          Capsules
          Powders & Granules
          Others
          Application Segments Covered in XYZResearch Market
          Specialty/Midsize
          Generics
          Big Pharma
          Other

          For any other requirements, please feel free to contact us and we will provide you customized report.

          Buy now